Breaking Finance News

Esperion Therapeutics (NDAQ:ESPR) has been upgraded from Underperform to Neutral in a statement by Credit Suisse earlier today.

Credit Suisse has upgraded Esperion Therapeutics (NDAQ:ESPR) from Underperform to Neutral in a statement released on 3/20/2017.

Having a price of $41.29, Esperion Therapeutics (NDAQ:ESPR) traded 52.64% higher on the day. The last stock close price is up 140.83% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time period. The company has recorded a 50-day moving average of $23.80 and a 200-day moving average of $15.00. 9,355,593 shares of ESPR traded, up from an avg. volume of 931,170

Recent Performance Chart

Esperion Therapeutics (NDAQ:ESPR)

Esperion Therapeutics has with a one year low of $9.40 and a one year high of $37.16 and has a market capitalization of $0.

A total of 12 analysts have released a report on Esperion Therapeutics. Three analysts rating the company a strong buy, eight analysts rating the company a buy, two analysts rating the company a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $32.67.

Brief Synopsis On Esperion Therapeutics (NDAQ:ESPR)

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.